I think at the end those companies which go private will relist if good corporate governance is established. A lack of transparency will force many US-listed China Reverse Take Overs and other small Chinese stocks to reconsider a listing in the U.S.
The nice thing of Tibet Pharmaceuticals is the fact that it has hardly (none?) institutional investors. So the going private procedure could go faster than normal. A Fairness Opinion will not be the case I guess.